Published in Obesity and Diabetes Week, June 20th, 2005
The company expects to initiate a phase II clinical trial for arimoclomol in June, 2005.
Jack Barber, PhD, senior vice president of drug development, said, "Arimoclomol has demonstrated neuroprotective efficacy in several preclinical animal models. We...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.